

5 April 2016 EMA/HMPC/84990/2015 *Corr*.¹ Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Thymus vulgaris* L. or *Thymus zygis* L., herba and *Primula veris* L. or *Primula elatior* (L.) Hill, radix

Final

Discussion in Working Party on European Union monographs	July 2010
and list (MLWP)	November 2010
	January 2011
Adoption by Committee on Herbal Medicinal Products (HMPC)	27 2011
for release for consultation	27 January 2011
End of consultation (deadline for comments)	15 August 2011
Re-discussion in MLWP	November 2011
	January 2012
	March 2012
	May 2012
	September 2012 (at HMPC request)
	November 2012
Adoption by Committee on Herbal Medicinal Products (HMPC)	
- opinion reached by consensus	24 September 2012
,	12 March 2013
- monograph and supporting documents	12 March 2013
Monograph (EMA/HMPC/130042/2010)	
AR (EMA/HMPC/130038/2010)	
List of references (EMA/HMPC/130045/2010)	
Overview of comments received during the public consultation	
(EMA/HMPC/897630/2011)	
HMPC Opinion (EMA/HMPC/332110/2012)	
First systematic review	
Discussion in MLWP	September 2014
	November 2014
Adoption by HMPC for release for consultation	28 January 2015
End of consultation (deadline for comments) ²	15 May 2015

¹ Correction to standard wording in section 4.2 (well-established use)



Re-discussion in MLWP	February 2016
Adoption by HMPC	5 April 2016

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; traditional
	use; Thymus vulgaris L. or Thymus zygis L., herba; Primula veris L. or Primula elatior
	(L.) Hill, radix; Thymi herba/Primulae radix; Thyme/Primula root

BG (bulgarski): Мащерка, стрък/Иглика, корен CS (čeština): tymiánová nať a prvosenkový kořen DA (dansk): Timian og Primularod DE (Deutsch): Thymian/Primelwurzel

EL (elliniká): Πόα Θύμου και ρίζα πριμούλης

EN (English): Thyme/Primula root

ES (español): Tomillo partes aéreas de/Prímula,

ET (eesti keel): liivatee ürt/nurmenuku juur FI (suomi): timjami / kevätesikko, juuri FR (français): Thym (parties aériennes de) /

Primevère (racine de)

HR (hrvatski): timijanova zelen / jaglačev

korijen

HU (magyar): Kakukkfű/kankalingyökér

IT (italiano): Timo foglia e fiore/Primula radice

(Primavera, Primula odorosa)

LT (lietuvių kalba): Vaistinių čiobrelių žolė ir raktažolių šaknys

LV (latviešu valoda): Timiānu laksti/Prīmulu saknes

MT (Malti): Timu u Primula

NL (Nederlands): Tijm / Sleutelbloem

PL (polski): Ziele tymianku/ Korzeń pierwiosnka

PT (português): Tomilho/Primavera, raiz RO (română): Iarbă de cimbru/Rădăcină de

ciuboţica cucului

SK (slovenčina): Vňať tymianu/Koreň prvosienky

SL (slovenščina): zel vrtne materine dušice /

korenina jegliča

SV (svenska): Timjan, ört / Gullviva, rot

IS (íslenska):

NO (norsk): Timian/Nøkleblomrot

² No comments were received during the period of public consultation. Therefore the final monograph is published together with the final assessment report and list of references, without an 'Overview of comments received during the public consultation'.

European Union herbal monograph on *Thymus vulgaris* L. or *Thymus zygis* L., herba and *Primula veris* L. or *Primula elatior* (L.) Hill, radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{3, 4}

Well-established use	Traditional use
With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Fixed combination of <i>Thymus vulgaris</i> L. <i>or Thymus zygis</i> L., herba and <i>Primula veris</i> L. or <i>Primula elatior</i> (L.) Hill, radix (Thyme and Primula root)	Fixed combination of <i>Thymus vulgaris</i> L. <i>or Thymus zygis</i> L., herba and <i>Primula veris</i> L. or <i>Primula elatior</i> (L.) Hill, radix (Thyme and Primula root)
i) Herbal substance	i) Herbal substance
Not applicable.	Not applicable.
ii) Herbal preparations	ii) Herbal preparations
a) Liquid extract from Thyme (DER 1:2-2.5), extraction solvent ammonia solution 10% m/m: glycerol 85% m/m: ethanol 90% V/V: water (1:20:70:109) and tincture from Primula root (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 50% V/V b) Liquid extract from Thyme (DER 1:2-2.5),	 a) Dry extract from Thyme (DER 6-10:1), extraction solvent ethanol 70% V/V and dry extract from Primula root (DER 3.5-4.5:1), extraction solvent water b) Liquid extract from Thyme (DER 1:2-2.5), extraction solvent ammonia solution 10% m/m: glycerol 85% m/m: ethanol 90% V/V: water (1:20:70:109) and soft extract
extraction solvent ammonia solution 10% m/m: glycerol 85% m/m: ethanol 90% V/V: water (1:20:70:109) and liquid extract from Primula root (DER 1:2-2.5), extraction solvent ethanol 70% m/m	from Primula root (DER 3-7:1), extraction solvent methanol: water: ammonia solution 26% (50:49.5:0.5) c) Liquid extract from Thyme (DER 1:2-2.5), extraction solvent ammonia solution 10%
c) Dry extract from Thyme (DER 6-10:1), extraction solvent ethanol 70% V/V and dry extract from Primula root (DER 6-7:1), extraction solvent ethanol 47.4% V/V	m/m: glycerol 85% m/m: ethanol 90% V/V: water (1:20:70:109) and soft extract from Primula root (DER 1-2:1), extraction solvent ethanol 55% V/V

³ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

European Union herbal monograph on *Thymus vulgaris* L. or *Thymus zygis* L., herba and *Primula veris* L. or *Primula elatior* (L.) Hill, radix EMA/HMPC/84990/2015

The material complies with the Ph. Eur. monograph (ref.: 0865 and 1364).

Well-established use	Traditional use
	d) Dry extract from Thyme (DER 4.5-7:1), extraction solvent methanol 25% V/V and dry extract from Primula root (DER 4-6:1), extraction solvent water
	e) Liquid extract from Thyme (DER 1:2-3), extraction solvent ethanol 20% V/V and liquid extract from Primula root (DER 1:2-3), extraction solvent ethanol 15% V/V
	f) Soft extract from Thyme (DER 5-7:1), extraction solvent methanol 25% V/V and soft extract from Primula root (DER 6-10:1), extraction solvent water
	g) Liquid extract from Thyme (DER 1:2-2.5), extraction solvent ammonia solution 10% m/m: glycerol 85% m/m: ethanol 90% V/V: water (1:20:70:109) and tincture from Primula root (Ratio herbal substance to extraction solvent 1:5), extraction solvent ethanol 50% V/V
	h) Liquid extract from Thyme (DER 1:2-2.5), extraction solvent ammonia solution 10% m/m: glycerol 85% m/m: ethanol 90% V/V: water (1:20:70:109) and liquid extract from Primula root (DER 1:2-2.5), extraction solvent ethanol 70% m/m
	i) Liquid extract from the mixture of Thyme (DER 1:3.3) and Primula root (DER 1:2-4.6), extraction solvent water

3. Pharmaceutical form

Well-established use	Traditional use
Herbal preparations in liquid or solid dosage forms for oral use.	Herbal preparations in liquid or solid dosage forms for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
Herbal medicinal product used as an expectorant in case of productive cough.	Traditional herbal medicinal product used as an expectorant in cough associated with cold.
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
Posology Adults and elderly	Posology Adolescents, adults and elderly
a) Single dose: Fixed combination of 0.43 g liquid Thyme extract and 0.21 g Primula root tincture Daily dose: 5 times daily	a) Single dose: Fixed combination of 75 mg dry Thyme extract and 37.5 mg dry Primula root extract Daily dose: 3 times daily
b) Single dose: Fixed combination of 0.5 g liquid Thyme extract and 0.25 g liquid Primula root extract Daily dose: 6 times daily	b) Single dose: Fixed combination of 1.13 g liquid Thyme extract and 0.045 g soft Primula root extract Daily dose: 3 times daily
c) Single dose: Fixed combination of 160 mg dry Thyme extract and 60 mg dry Primula root extract Daily dose: 3 times daily	c) Single dose: Fixed combination of 1.16 g liquid Thyme extract and 0.17 g soft Primula root extract Daily dose: 4 times daily
The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Duration of use	d) Single dose: Fixed combination of 110 mg dry Thyme extract and 21 mg dry Primula root extract Daily dose: 3 times daily
If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a pharmacist should be consulted.	e) Single dose: Fixed combination of 1.24 g liquid Thyme extract and 0.41 g liquid Primula root extract Daily dose: 3-5 times daily
Method of administration Oral use	f) Single dose: Fixed combination of 128 mg soft Thyme extract and 18 mg soft Primula root extract. Daily dose: 3-4 times daily
	i) Single dose: 3.08 g equivalent to 0.62 g of Thyme and 0.22–0.51 g of Primula root. Daily dose: 4 times daily

Well-established use	Traditional use
	Adolescents
	 g) Single dose: Fixed combination of 0.43 g liquid Thyme extract and 0.21 g Primula root tincture Daily dose: 5 times daily
	 h) Single dose: Fixed combination of 0.5 g liquid Thyme extract and 0.25 g liquid Primula root extract Daily dose: 6 times daily
	Children between 4 and 11 years of age
	c) Single dose: Fixed combination of 0.77 g liquid Thyme extract and 0.12 g soft Primula root extract Daily dose: 3-4 times daily
	g) Single dose: Fixed combination of 0.36 g liquid Thyme extract and 0.18 g Primula root tincture Daily dose: 3-5 times daily
	 h) Single dose: Fixed combination of 0.33 g liquid Thyme extract and 0.17 g liquid Primula root extract Daily dose: 3-5 times daily
	Herbal preparations a, b, d, e, f, i
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Herbal preparation c, g, h
	The use in children under 4 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use

4.3. Contraindications

Well-established use	Traditional use
Hypersensitivity to the active substances or to	Hypersensitivity to the active substances or to
other plants of the Lamiaceae family.	other plants of the Lamiaceae family.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
If dyspnoea, fever or purulent sputum occurs, a doctor or a pharmacist should be consulted. Caution is recommended in patients with gastritis or gastric ulcer. If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist should be consulted. The use in children and adolescents under 18 years of age has not been established due to lack of data on efficacy. For tinctures and extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package	If dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. Caution is recommended in patients with gastritis or gastric ulcer. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. For tinctures and extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.
leaflet of medicinal products for human use', must be included.	Herbal preparations a, b, d, e, f, i The use in children under 12 years of age has not been established due to lack of adequate data. Herbal preparation c, g, h The use in children under 4 years of age has not been established because medical advice should be sought.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
None reported.	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
Safety during pregnancy and lactation has not	Safety during pregnancy and lactation has not
been established. In the absence of sufficient	been established. In the absence of sufficient
data, the use during pregnancy and lactation is	data, the use during pregnancy and lactation is

Well-established use	Traditional use
not recommended.	not recommended.
No fertility data available.	No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
No studies on the effect on the ability to drive	No studies on the effect on the ability to drive
and use machines have been performed.	and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
Gastric disorders and nausea may occur. The frequency is not known.	Gastric disorders and nausea may occur. The frequency is not known.
If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
No case of overdose has been reported.	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
Pharmacotherapeutic group: respiratory system	Not required as per Article 16c(1)(a)(iii) of
Proposed ATC code: R05 C	Directive 2001/83/EC as amended.
The mechanism of action is not known.	

5.2. Pharmacokinetic properties

Well-established use	Traditional use
No data available.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
Not applicable.	Not applicable.

7. Date of compilation/last revision

5 April 2016